GlassScriptPhysician profile
Robert S Dean
NPI 1326042011
$37,246.32
in general payments reported to CMS, 2019-2025
18 companies · $1,572 in 2025
The $1,572 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $158 · 2021: $395 · 2022: $7,748 · 2023: $13K · 2024: $14K · 2025: $1,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Consulting Fee: $7,000 · Food and Beverage: $1,656 · Travel and Lodging: $1,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,350.00 |
| Consulting Fee | $7,000.00 |
| Food and Beverage | $1,656.00 |
| Travel and Lodging | $1,425.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $34,014.73 | 2019-2025 | Exalt Model D, Spybite, Resolution Clip |
| Olympus Corporation of The Americas | $1,711.75 | 2022-2023 | Single Use Electrosurgical Hemostatic Forceps, Single Use Electrosurgical Knife Kd-655 |
| Abbvie INC. | $370.54 | 2019-2025 | Rinvoq, Skyrizi |
| Intercept Pharmaceuticals, INC. | $154.49 | 2023 | Ocaliva |
| Cook Medical LLC | $133.22 | 2019 | |
| Gilead Sciences, INC. | $125.00 | 2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $122.91 | 2019-2020 | |
| Romark Laboratories, Lc | $114.96 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $98.38 | 2021 | |
| Olympus America INC. | $87.76 | 2019-2025 | Hanarostent Esophagus Tts(Ccc), Endoclot Phs, Single Use Repositionable Clip |
| Ambu INC. | $83.82 | 2022 | |
| Qol Medical, LLC | $48.36 | 2021-2024 | Sucraid |
| Braintree Laboratories, INC. | $45.71 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $35.80 | 2022-2024 | Rebyota |
| Novo Nordisk INC | $34.07 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $32.26 | 2019 | |
| Shionogi INC | $18.32 | 2019 | |
| Merck Sharp & Dohme LLC | $14.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.